Avastin's Last Hope For Breast Cancer Claim May Be Subpopulations
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee votes to remove the breast cancer treatment indication from the Genentech drug's label after failed confirmatory trial, but two more studies are on their way.
You may also be interested in...
Genentech's Hopes For Avastin In Breast Cancer May Rest With New ODAC Members
FDA presiding officer Karen Midthun again rebuffs the company's request to convene experts other than the Oncologic Drugs Advisory Committee, but notes that new members are expected to join the panel before the June 28-29 hearing on withdrawing bevacizumab's accelerated approval.
Genentech's Hopes For Avastin In Breast Cancer May Rest With New ODAC Members
FDA presiding officer Karen Midthun again rebuffs the company's request to convene experts other than the Oncologic Drugs Advisory Committee, but notes that new members are expected to join the panel before the June 28-29 hearing on withdrawing bevacizumab's accelerated approval.
Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim
Agency officials stress that FDA is eager to work with Genentech on future studies to identify a subpopulation of responders.